Curcumin Biomarkers

University of North Carolina, Chapel Hill40 enrolled

Overview

Colorectal cancer is a major problem in the United States and other developed countries. A safe and effective chemopreventive agent could reduce the burden of colorectal neoplasia. Curcumin, is a product that is derived from Curcuma longa. It has been used for thousands of years as a traditional remedy. Curcumin blocks a number of targets involved in tumor initiation, promotion, and progression, and is considered a promising chemopreventive agent. The investigators propose to enroll 40 patients after screening colonoscopy who will have rectal biopsies at baseline and after 4 weeks of curcumin 4 grams per day. The investigators will use microarray analysis to identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies. The study will also evaluate tolerability and toxicity.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 40 - 80. 2. A willingness to follow the study protocol, as indicated by provision of informed consent to participate 3. Good general health Exclusion Criteria: 1. Familial colorectal cancer syndromes (e.g. Hereditary Non-Polyposis Colon Cancer, Familial Adenomatous Polyposis) 2. Ulcerative colitis or Crohn's disease. 3. History of large bowel resection for any reason 4. Diagnosed narcotic or alcohol dependence 5. Unwillingness to forgo curcumin/turmeric-containing supplements during the trial or consumption of curry/turmeric at meals \> 3 times a week. 6. Allergy to turmeric/curcumin. 7. Women with childbearing potential who do not agree to practice effective birth control. 8. Individuals with creatinine, AST or ALT above 1.5 times the upper limit of normal at baseline. 9. Personal or inherited bleeding disorders or therapeutic anti-coagulation with warfarin. 10. Women who are pregnant or nursing. 11. Individuals who have taken antibiotics within the three months prior to enrollment.

Outcomes

Primary Outcomes

Gene expression

Change in gene expression

Time frame: 30 days

Ribonucleic acid (RNA) level

Transcript level as mRNA copies per cell

Time frame: 30 days

Apoptosis

Immunohistochemistry (IHC) signal as intensity and proportion of cells stained

Time frame: 30 days

Secondary Outcomes

Number of Participants with Adverse Events

Time frame: 30 days

Curcumin Biomarkers

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes